UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 621, 2005

MICRO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-06523

33-0569235

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

2 Goodyear, Irvine, California 92618

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (949) 837-3700

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On July 621, 2005, Micro Therapeutics, Inc. ~~issued~~received apre-market ~~press~~application ~~release~~approval from the U.S. Food and Drug Administration to ~~report~~ commercialize its Onyx® ~~net~~Liquid ~~sales~~Embolic System for the ~~fiscal~~treatment ~~second~~of ~~quarter~~arterio-venous ~~ended~~malformations, ~~July~~a 3,vascular ~~2005~~disorder in the brain. ~~The~~A copy of the press release announcing the approval is ~~furnished~~attached hereto as Exhibit 99.1 ~~and is incorporated herein by reference~~.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(c)

Exhibits

ExhibitNumber		Description
Exhibit Number		Description
99.1		Press Release dated July 621, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		MICRO THERAPEUTICS, INC.
July 7, 2005		/s/ Thomas Wilder
July 22, 2005		/s/ Thomas C. Wilder, III
		Thomas C. Wilder, III, President and
		Thomas C. Wilder, III, President and Chief Executive Officer
		Chief Executive Officer

EXHIBIT INDEX

ExhibitNumber		Description
99.1		Press Release dated July 621, 2005.

Filing Compare · MICRO THERAPEUTICS INC